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Background: Immediate recurrence of atrial ﬁbrillation (AF) after radiofrequency (RF) catheter ablation is
commonly observed within 3 d after the procedure. The mechanism and pharmacological management
of immediate AF recurrence remain unclear.
Methods: A total of 50 consecutive patients with paroxysmal AF were randomized to receive either low-
dose landiolol (landiolol group) or a placebo (placebo group). In the landiolol group, intravenous
landiolol (0.5 μg kg1 min1) was administered for 3 d after AF ablation.
Results: No serious adverse event associated with RF catheter ablation or landiolol administration was
observed. The prevalence of immediate AF recurrence (r3 d after RF catheter ablation) was signiﬁcantly
lower in the landiolol group than in the placebo group (16% vs. 48%, p¼0.015). Although the postprocedural
change in heart rate was signiﬁcantly lower in the landiolol group compared to that in the placebo group,
the changes in blood pressure and body temperature were not different between the two groups. Multiple
logistic regression analysis revealed that landiolol treatment was the only independent predictor of
immediate AF recurrence after ablation (odds ratio: 0.180; 95% conﬁdence interval: 0.044–0.729; p¼0.016).
Conclusions: Prophylactic administration of low-dose landiolol after AF ablation may be effective and safe
for preventing immediate AF recurrence within 3 d after AF ablation.
& 2015 Japanese Heart Rhythm Society. Published by Elsevier B.V. All rights reserved.
1. Introduction
Radiofrequency (RF) catheter ablation is becoming an effective
therapy for drug-resistant atrial ﬁbrillation (AF) [1]. However,
the rate of AF recurrence after successful RF catheter ablation remains
relatively high [2], and recurrences are common within 3 d after the
procedure [3,4]. Immediate AF recurrence interferes with postproce-
dural management, prolongs hospital stays, and increases healthcare
costs. However, immediate pharmacological management after AF
ablation is often difﬁcult because of a lack of drugs with both good
efﬁcacy and dose adjustability. Therefore, a new treatment strategy is
needed for preventing immediate AF recurrence after ablation.
Although there is considerable evidence for a mechanistic link
between cardiac sympathetic nervous dysfunction and the develop-
ment of AF [5,6], it is not clear whether sympathetic nerve activity
is related to immediate AF recurrence after catheter ablation. As left
atrial (LA) ganglionated plexi is present in the vicinity of the
pulmonary vein (PV), RF energy applications around the PV affect
sympathetic nervous activation [7] and may be associated with
immediate AF recurrence after catheter ablation. Several recent
studies have described the efﬁcacy of landiolol hydrochloride, an
ultra-short-acting beta adrenoceptor antagonist, for the prevention of
AF after open-heart surgery [8–11]. It has mainly been used to treat
AF after cardiovascular surgery. Because of its extremely short half-
life (4 min) and high β1 selectivity, landiolol may also be useful for
controlling AF after RF catheter ablation without major side effects.
At low doses, landiolol exerts a clinically relevant negative chrono-
tropic effect without negative inotropic effects [11–14]. Accordingly,
the purpose of the present study was to investigate the prophylactic
effect of continuous low-dose landiolol administration against
immediate AF recurrence after catheter ablation.
2. Methods
2.1. Patients
This study included 50 consecutive patients with symptomatic,
drug-resistant, non-valvular paroxysmal AF who underwent RF
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catheter ablation at Yamagata University Hospital (Table 1). All patients
had symptomatic, paroxysmal AF, which was deﬁned as AF episodes
that spontaneously terminated and lasted for 430 s and o7 d during
treatment with antiarrhythmic drugs (AADs). All AADs were discon-
tinued ﬁve half-lives before AF ablation with the exception of amiodar-
one, which was discontinued at least 6 weeks before the RF procedure.
Patients who were treated with oral β-blockers, angiotensin-converting
enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and/or
statins at study enrollment continued to take these drugs with no
change in dose until the end of AF ablation. Ethical approval was
obtained from the institutional review committee (approval date,
February 15, 2010; approval number, 148), and all patients gave their
informed, written consent before participation.
2.2. Study protocol
This study was designed as a prospective, randomized, single blind
study. All patients were equally randomized for treatment with
landiolol (landiolol group) or a placebo (placebo group) on the ﬁrst
day of their hospitalization. In the landiolol group, 1 mg/mL of land-
iolol hydrochloride (Onoact, Ono Pharmaceutical Co., Osaka, Japan) in
a 0.9% sodium chloride solution was administrated intravenously
(0.5 μg kg1 min1) for 3 d immediately after catheter ablation [15].
A placebo solution (0.9% sodium chloride) was intravenously adminis-
tered to patients in the placebo group. All patients remained hospi-
talized under continuous rhythm monitoring from admission to
discharge. Immediate AF recurrence was deﬁned as AF or atrial
tachycardia (AT) lasting 45min [10]. The primary end points of the
study were the proportion of patients who were free of recurrent AF/
AT in the 3 d immediately after catheter ablation and any serious
complications caused by catheter ablation or landiolol treatment.
2.3. RF catheter ablation
Extensive PV isolation was performed with 3-dimensional map-
ping (CARTOs, Biosense Webster Inc., USA). After transseptal
catheterization, a 7-Fr 10-polar ring catheter (Lasso, Biosense
Webster, Inc., Diamond Bar, CA, USA) and a 7-Fr quadripolar
ablation catheter with a 3.5-mm distal electrode and deﬂectable
tip (ThermoCool, Biosense Webster) were positioned in the LA.
Intravenous heparin was given to maintain an activated clotting
time of 300–350 s during the entire procedure. After selective PV
angiography, a single Lasso catheter was then positioned inside the
PV within 5 mm of the ostium to map PV potentials. RF energy was
delivered using the temperature control mode with a target
temperature of 42 1C and a maximum power output of 25–35W.
The endpoint of extensive PV isolation was the creation of an
extensive ipsilateral bidirectional conduction block, which was
conﬁrmed from the atrium to the PV and vice versa. In addition,
the bidirectional conduction block was reconﬁrmed at least 60 min
after successful PV isolation [6]. After PV isolation, if AF was
sustained or induced with coronary sinus (CS) burst pacing at a
Table 1
Baseline patient characteristics.
All patients (n¼50) Placebo group (n¼25) Landiolol group (n¼25) p-Value
Age, years 5879 59710 5778 0.193
Male gender, n (%) 39 (78) 21 (84) 18 (72) 0.306
Systolic blood pressure, mmHg 118714 119712 117716 0.593
Diastolic blood pressure, mmHg 72710 7279 72711 0.855
Heart rate, bpm 6479 62711 6678 0.148
Duration of AF history, months (IQR) 38 (19–88) 35 (10–69) 39 (23–101) 0.218
CHADS2 score, 0/1/2 25/21/4 16/8/1 9/13/3 0.126
Structural heart disease 8 (16) 3 (12) 5 (20) 0.700
Hypertension, n (%) 22 (44) 11 (44) 11 (44) 1.000
Diabetes mellitus, n (%) 4 (8) 1 (4) 3 (12) 0.602
TIA/stroke, n (%) 0 (0) 0 (0) 0 (0) –
Dyslipidemia, n (%) 22 (44) 13 (52) 9 (36) 0.255
Medications
ACE inhibitors or ARBs, n (%) 14 (28) 6 (24) 8 (32) 0.529
Oral β-blocker, n (%) 22 (44) 10 (40) 12 (48) 0.569
Statin, n (%) 10 (20) 4 (16) 6 (24) 0.724
Ineffective AADs
Number of ineffective AADs (IQR) 3 (1–3) 2 (1–3) 3 (2–3) 0.337
Class I, n (%) 45 (90) 24 (96) 21 (84) 0.346
Amiodarone, n, (%) 8 (16) 1 (4) 7 (28) 0.054
Bepridil, n (%) 13 (26) 6 (24) 7 (28) 0.747
Laboratory data
eGFR, mL/min 1.73 cm2 78716 80714 77717 0.492
hsCRP, mg/dL (IQR) 0.041 (0.027–0.077) 0.034 (0.024–0.055) 0.056 (0.029–0.090) 0.140
BNP, pg/mL (IQR) 34 (15–50) 25 (14–48) 37 (22–66) 0.048
Echocardiographic parameters
LA diameter, mm 3976 3976 3976 1.000
LV end-diastolic dimension, mm 5075 4974 5075 0.749
LV ejection fraction, % 6477 6476 6479 0.969
RF catheter ablation
Fluoroscopy time, min 87728 80721 96732 0.054
Procedure time, min 233748 241750 224746 0.221
CTI blockline, n (%) 14 (28) 8 (32) 6 (24) 0.529
CFAE ablation, n (%) 13 (26) 8 (32) 5 (20) 0.333
Data are presented as mean7standard deviation. AAD, antiarrhythmic drug; ACE, angiotensin converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker;
BNP, B-type natriuretic peptide; CHADS2, congestive heart failure; hypertension; age Z75; diabetes mellitus; prior stroke, transient ischemic attack, or thromboembolism;
CFAE, complex fractionated atrial electrogram; CTI, cavotricuspid isthmus; eGFR, estimated glomerular ﬁltration rate; hsCRP, high-sensitivity C-reactive protein; IQR,
interquartile range; LA, left atrium; LV, left ventricle; RF, radiofrequency; TIA, transient ischemic attack.
D. Ishigaki et al. / Journal of Arrhythmia 31 (2015) 279–285280
cycle length up to 200 ms and lasted 43 min [6,16], RF catheter
ablation targeting for complex fractionated atrial electrogram
(CFAE) was added. If AF did not terminate or was inducible after
these procedures, sinus rhythm was restored by transthoracic
cardioversion. A cavotricuspid isthmus (CTI) block line was created
in patients with coexistence of an atrial ﬂutter with a conﬁrmed
bidirectional block.
2.4. Heart rate, blood pressure, body temperature and C-reactive
protein
The patients' heart rates, blood pressures, and body tempera-
tures were measured every 8 h during the four consecutive
days before and after RF catheter ablation. The changes in heart
rate, blood pressure, and body temperature were deﬁned as the
difference in values between baseline and during the 3 d after
ablation. The change in C-reactive protein (CRP) level was also
measured as the difference in CRP 1 d before and 1 d after AF
ablation.
2.5. Mid-term follow-up
Patients remained hospitalized under continuous rhythm monitor-
ing for at least 3 d after the procedure, andwere followed for at least 12
months after AF ablation. After discharge, all patients were seen in our
hospital, at the outpatient arrhythmia clinic, or by their referring
physician at 2 weeks and 1month, and then every 3months thereafter.
At each hospital visit, the patients underwent 12-lead electrocardio-
graphy and intensive questioning regarding any arrhythmia-related
symptoms. Holter electrocardiography and portable electrocardio-
graphic monitoring (HCG-901, OMRON, Kyoto, Japan) were performed
for any patient reporting symptoms suggesting recurrent arrhythmia.
Telephone interviews were also carried out for all patients at the end of
follow-up. If the electrocardiogram showed any AF episodes during
follow-up, patients received a diagnosis of clinical recurrence of AF,
irrespective of the presence of symptoms. Repeat ablation was not
performed in any of the patients during the study period.
2.6. Statistical analysis
Continuous variables were expressed as means7standard
deviation. Skewed variables were presented as medians with
interquartile ranges. We employed Student's t-test and the chi-
square test to compare continuous and categorical variables,
respectively. When the data were not normally distributed, the
Mann–Whitney U test was used. Univariate analysis with logistic
regression analysis was used to identify signiﬁcant predictors of
immediate AF recurrence within 3 d of RF catheter ablation. All
parameters with po0.10 in the univariate analysis were entered
into the multivariable analysis. AF-free curves were constructed
based on the Kaplan–Meier method and compared using log-rank
tests. A p-value o0.05 was considered statistically signiﬁcant.
3. Results
3.1. Baseline characteristics
The baseline characteristics of the study group are summarized
in Table 1. The mean patient age was 5879 years, and the
majority was male (78%). Overall, 22 (44%), four (8%), and 22
(44%) patients had hypertension, diabetes mellitus, and dyslipide-
mia, respectively, and these rates did not differ between the two
groups. Baseline blood pressure, heart rate, and duration of AF
history were not different between the two groups. CHADS2
(congestive heart failure; hypertension; ageZ75; diabetes melli-
tus; prior stroke, transient ischemic attack, or thromboembolism)
scores were also not signiﬁcantly different between the two
groups. Neither prior stroke nor transient ischemic attack was
observed in the present study. Although no differences were found
for medications or the number of ineffective AADs, patients in the
landiolol group tended to receive amiodarone more frequently
(p¼0.054). The plasma level of brain natriuretic peptide was
slightly higher in the landiolol group than in the placebo group
(p¼0.048). LA diameter, left ventricular end-diastolic dimension,
and left ventricular ejection fraction were not different between
the two groups.
3.2. RF catheter ablation
Extensive PV isolation was achieved in all patients. The creation
of a bidirectional block line at the CTI and RF catheter ablation
targeting for CFAE were performed in 14 (28%) and 13 (26%)
patients, respectively. The mean ﬂuoroscopy and procedure times
were 87728 min and 233748 min, respectively.
3.3. Immediate AF recurrence within 3 d after ablation
The patients remained hospitalized under continuous rhythm
monitoring for at least 3 d after the procedure. No patients experi-
enced adverse events attributable to landiolol administration such as
bradycardia, hypotension, or liver dysfunction. During the 3 d after
ablation, AF recurrences were less frequently observed in the landiolol
group than in the placebo group (16% [4/25] vs. 48% [12/25], p¼0.015;
Fig. 1A). Among patients who did not receive oral β-blockers, AF
p = 0.015
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Fig. 1. Prevalence of atrial ﬁbrillation (AF) recurrence within 3 d of catheter ablation. Recurrence was deﬁned as AF or atrial tachycardia lasting longer than 5 min. (A) All
patients. (B) Patients not taking oral β-blockers. (C) Patients taking oral β-blockers.
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recurrences were also less frequently observed in the landiolol group
than in the placebo group (8% [1/13] vs. 47% [7/15], p¼0.023; Fig. 1B).
Although AF recurrences tended to be less frequently observed in the
patients in the landiolol group who took oral β-blockers compared to
the patients in the placebo group on oral β-blockers, this difference
was statistically insigniﬁcant (25% [3/12] vs. 50% [5/10], p¼0.225;
Fig. 1C).
3.4. Change in heart rate, blood pressure, body temperature, and CRP
levels
Although heart rate elevation after RF catheter ablation was
signiﬁcantly lower in the landiolol group than in the placebo
group (Fig. 2), the changes in blood pressure and body tempera-
ture before and after AF ablation were not signiﬁcantly different
between the two groups (Figs. 3 and 4). The change in CRP level
was also not different between the landiolol group and the
placebo group (Fig. 5).
3.5. Predictors of immediate AF recurrence after ablation
Univariate logistic regression analysis revealed that landiolol
treatment was the only predictor of immediate AF recurrence after
ablation (odds ratio [OR]: 0.206, 95% conﬁdence interval [CI]:
0.055–0.777, p¼0.020). Multivariate logistic regression analysis,
including factors with signiﬁcance o0.10 by univariate analysis,
revealed that landiolol treatment was the only independent factor
affecting the prevention of immediate AF recurrence after ablation
(OR: 0.180, 95% CI: 0.044–0.729, p¼0.016; Table 2).
3.6. Mid-term follow-up after ablation
After a 3-month blanking period, β-blockers and AADs were
discontinued in all patients. During a median 15-month follow-up
after RF catheter ablation (range, 12–50.8 months), AF recurrences
were conﬁrmed in 13 patients (52%) in the placebo group and nine
patients (36%) in the landiolol group. The AF-free rate post-
ablation tended to be greater in the landiolol group than in the
placebo group (p¼0.126). No AT or serious complication was noted
for any of the patients.
4. Discussion
The results of this study demonstrate that (1) low-dose land-
iolol (0.5 μg kg1 min1) prevent heart rate elevation after AF
ablation; (2) prophylactic administration of low-dose landiolol
successfully prevented immediate AF recurrence within 3 d after
AF ablation without any adverse effects.
RF energy applications to the LA evoke an inﬂammatory response,
which can cause subsequent AF recurrence shortly after AF ablation.
Oral et al. performed PV isolation in 110 consecutive AF patients, and
found that early AF recurrence occurred in 35% of patients at a mean of
3.773.5 d after the procedure. The recurrence of AF was most
frequently observed within 3 d of the procedure in approximately
70% of cases [3]. The transient use of small amounts of corticosteroids,
such as intravenous hydrocortisone the day of the procedure and oral
prednisolone for 3 d afterward, was reported to prevent immediate AF
recurrences [16]. Recently, anti-inﬂammatory treatment by colchicine
to reduce early recurrences after AF ablationwas reported by Deftereos
et al. [17]. These effects seem to be associated with decreased levels of
inﬂammatory mediators, including body temperature, CRP, and
interleukin-6 levels. Earlier reports demonstrated that relatively high-
dose landiolol (2–5 μg kg1 min1) exerted an anti-inﬂammatory
effect and could prevent AF after cardiac surgery [8,9]. Even though
low-dose landiolol (0.5 μg kg1 min1) did not suppress CRP levels
after AF ablation, AF recurrence was less frequent in the landiolol
group. Landiolol may be superior to corticosteroids and colchicine for
the prevention of immediate AF recurrence. Corticosteroids cause
several side effects such as infections, rise in blood glucose level, and
gastric ulcer. In particular, upper gastrointestinal side effects are a
common risk in patients after AF ablation [18]. In addition, compared
with oral anti-inﬂammatory drugs, landiolol is safer when side effects
occur. Intravenously administered landiolol has an extremely short
half-life (4 min) compared with oral drugs.
Cardiac sympathetic nerve over-activity is also associated with
AF occurrence after cardiac surgery [19]. Sympathetic nerve disin-
tegrity enhances automaticity or triggered activity, stimulating the
ﬁbrillation process, and shortens atrial refractoriness in a non-uniform
fashion that favors AF perpetuation [19]. High washout rate of iodine-
123-metaiodobenzylguanidine imaging and enhanced cardiac sympa-
thetic tone were independently associated with AF recurrence after
catheter ablation [6]. Landiolol suppresses the postprocedural heart
rate and AF onset without lowering CRP levels, which suggests that
controlling excessive sympathetic activity might be the most plausible
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Fig. 2. (A) Mean heart rate during the study period. (B) Change in heart rate between baseline and the initial 3 d after catheter ablation.
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reason for the effectiveness of landiolol in the present study. We
administered a low-dose infusion of landiolol (0.5 μg kg1 min1) [15]
at a rate lower than those described in other studies to minimize the
incidence of side effects. Fujiwara et al. reported that infusion of
landiolol (1.5–2.5 μg kg1 min1) for 2 d after coronary artery bypass
grafting had a preventive effect on the appearance of AF without
suppressing cardiac function [10]. In a study published by Sezai et al.,
administration of landiolol at 2 μg kg1 min1 from the time of central
anastomosis during coronary artery bypass grafting and for 2 subse-
quent days was associated with a lower incidence of AF [8]. Because RF
catheter ablation is a relatively non-invasive procedure, low-dose
landiolol may have been effective for preventing immediate AF
recurrence. Interestingly, our subgroup analysis revealed that landiolol
was more effective among patients not taking oral β-blockers com-
pared to those taking oral β-blockers. Prophylactic low-dose landiolol
therapymay be more suitable for patients not taking oral β-blockers. In
addition, none of the patients developed hypotension or bradycardia,
indicating the safety of low-dose landiolol administration after AF
ablation.
A previous study reported that patients with early AF recur-
rences were signiﬁcantly less likely to have long-term freedom
from recurrent AF than patients without early recurrences [3]. In
the present study, landiolol administration tended to improve the
mid-term prognosis compared to placebo. In a previous study,
corticosteroid administration shortly after AF ablation effectively
prevented AF recurrences immediately after ablation and during a
14-month follow-up period [16]. Electrical remodeling (shortening
of atrial refractoriness) proceeds within a few days of AF and
contributes to increased AF stability, whereas reverse remodeling
after the restoration of sinus rhythm occurs much more slowly
[20]. A longer AF-free period after AF ablation might have enabled
the atria to inhibit electrical, contractile, and structural remodeling
and facilitated reverse remodeling, resulting in a greater AF-free
rate during the mid-term follow-up period. It is possible that
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sympathetic activity control immediately after RF application may
be important for long-term AF prevention, but the underlying
mechanism remains unclear.
This study has several limitations. First, the amount of landiolol
administered in this study was lower than that in previous reports.
High-dose landiolol administration may have anti-inﬂammatory
activity and may exert more preventative effects compared to low-
dose landiolol. Second, the preventive value of oral β-blocker use
was not investigated in the present study. Recent reports showed
that the selective β1 receptor antagonist bisoprolol is more
effective than carvedilol in decreasing the incidence of AF after
coronary artery bypass grafting [21] and severe heart failure [22].
β1-Selective oral antagonist administration may also suppress
immediate AF recurrence after catheter ablation. Finally, landiolol
administration tended to improve the mid-term prognosis com-
pared to placebo in the present study. If this study included many
more subjects, the preventative effect of landiolol might have been
conﬁrmed during mid-term follow up.
5. Conclusion
Prophylactic low-dose landiolol (0.5 μg kg1min1) therapy
within 3 d of RF catheter ablation is effective and safe for preve-
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Fig. 5. Change of C-reactive protein level between baseline and 1 d after catheter
ablation.
Table 2
Univariate and multivariate analyses of immediate AF recurrence after catheter ablation.
Odds ratio 95% Conﬁdence interval p-Value
Univariate analysis
Age, per 1 year increase 1.013 0.946–1.086 0.705
Male 0.778 0.191–3.167 0.726
Duration of AF history, per 1 month increase 1.003 0.992–1.014 0.594
CHADS2 score, per 1 point increase 0.436 0.151–1.261 0.126
Presence of
Structural heart disease 0.257 0.029–2.294 0.224
Hypertension 0.296 0.079–1.106 0.070
Diabetes mellitus 0.689 0.066–7.192 0.756
Dyslipidemia 1.429 0.433–4.717 0.558
Use of
ACE inhibitors or ARBs 0.262 0.051–1.350 0.109
Oral b-blocker 1.429 0.433–4.718 0.558
Statin 0.890 0.197–4.012 0.880
AADs, per 1 drug increase 1.401 0.905–2.168 0.131
Amiodarone 0.257 0.029–2.294 0.224
Bepridil 2.314 0.625–8.575 0.209
Laboratory data
eGFR, per SD (15.6 mL/min 1.73 cm2) increase 1.013 0.693–2.305 0.431
CRP before ablation, per SD (0.14 mg/dL) increase 0.711 0.290–1.749 0.457
CRP after ablation, per SD (0.59 mg/dL) increase 0.632 0.282–1.419 0.267
BNP, per SD (46.2 pg/mL) increase 0.562 0.227–1.393 0.212
Echocardiographic parameters
LA diameter, per SD (5.9 mm) increase 1.027 0.563–1.871 0.932
LV end-diastolic dimension, per SD (4.8 mm) increase 0.729 0.388–1.368 0.325
LV ejection fraction, per SD (7.2%) increase 0.597 0.318–1.121 0.109
RF catheter ablation
Procedure time, per 1 min increase 1.002 0.990–1.015 0.748
CFAE ablation 1.477 0.394–5.536 0.563
Others
Landiolol treatment 0.206 0.055–0.777 0.020
Change of systolic BP, per 1 mmHg increase 0.966 0.905–1.030 0.289
Change of diastolic BP, per 1 mmHg increase 0.991 0.926–1.062 0.807
Change of heart rate, per 1 bpm increase 0.988 0.933–1.046 0.674
Change of CRP, 1 mg/dL increase 0.644 0.201–2.059 0.458
Multivariate analysis
Hypertension 0.249 0.060–1.032 0.055
Landiolol treatment 0.180 0.044–0.729 0.016
AAD, antiarrhythmic drug; ACE, angiotensin-converting enzyme; AF, atrial ﬁbrillation; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; BP, blood pressure;
CHADS2, congestive heart failure; hypertension; age Z75; diabetes mellitus; prior stroke, transient ischemic attack, or thromboembolism; CFAE, complex fractionated atrial
electrogram; CRP, C-reactive protein; CTI, cavotricuspid isthmus; eGFR, estimated glomerular ﬁltration rate; LA, left atrium; LV, left ventricle; RF, radiofrequency; TIA,
transient ischemic attack.
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nting immediate AF recurrence within 3 d after AF ablation. This
result indicated the relationship between sympathetic nervous
activity and immediate AF recurrence after catheter ablation.
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